Get the Stockscreener App
1.58
4.82%
-0.08
After Hours:
1.57
-0.01
-0.63%
Macrogenics Inc stock is traded at $1.58, with a volume of 533.40K.
It is down -4.82% in the last 24 hours and down -11.24% over the past month.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
See More
Previous Close:
$1.66
Open:
$1.65
24h Volume:
533.40K
Relative Volume:
0.70
Market Cap:
$99.87M
Revenue:
$139.77M
Net Income/Loss:
$-97.62M
P/E Ratio:
-1.00
EPS:
-1.58
Net Cash Flow:
$-61.71M
1W Performance:
-17.28%
1M Performance:
-11.24%
6M Performance:
-9.71%
1Y Performance:
-59.17%
1-Day Range:
$1.54
$1.69
1-Week Range:
$1.54
$1.94
52-Week Range:
$0.9897
$5.10
Macrogenics Inc Stock (MGNX) Company Profile
Name
Macrogenics Inc
Sector
Industry
Phone
301-251-5172
Address
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
1.58 | 104.92M | 139.77M | -97.62M | -61.71M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Resumed | Barclays | Overweight |
| Nov-07-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Aug-01-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-31-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-31-24 | Downgrade | Guggenheim | Buy → Neutral |
| May-10-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-10-24 | Downgrade | Stifel | Buy → Hold |
| May-10-24 | Downgrade | TD Cowen | Buy → Hold |
| Apr-26-24 | Initiated | B. Riley Securities | Buy |
| Apr-09-24 | Upgrade | TD Cowen | Hold → Buy |
| Mar-04-24 | Reiterated | BTIG Research | Buy |
| Feb-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-17-23 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-22-22 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-14-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-18-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Jul-11-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-04-22 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-28-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-04-22 | Initiated | SMBC Nikko | Outperform |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-12-21 | Upgrade | Barclays | Underweight → Overweight |
| Dec-22-20 | Resumed | H.C. Wainwright | Buy |
| Aug-03-20 | Downgrade | Citigroup | Buy → Neutral |
| Jun-01-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-26-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Dec-19-19 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-19 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-21-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Guggenheim | Neutral |
| Feb-07-19 | Upgrade | Citigroup | Sell → Buy |
| Feb-07-19 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-06-19 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-04-19 | Downgrade | Citigroup | Neutral → Sell |
| Dec-10-18 | Downgrade | Raymond James | Outperform → Underperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| May-31-18 | Initiated | Evercore ISI | Outperform |
| Mar-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-31-17 | Initiated | Raymond James | Outperform |
View All
Macrogenics Inc Stock (MGNX) Latest News
HC Wainwright & Co. Reiterates MacroGenics (MGNX) Neutral Recommendation - Nasdaq
Can MacroGenics Inc. stock hit record highs againEarnings Risk Report & Real-Time Volume Spike Alerts - newser.com
Will MacroGenics Inc. stock rally after Fed decisionsMarket Growth Report & Safe Capital Growth Tips - newser.com
MGNX: HC Wainwright Reiterates Neutral Rating with $2.00 Price Target | MGNX Stock News - GuruFocus
How to escape a deep drawdown in MacroGenics Inc.Trade Ideas & Long-Term Investment Growth Plans - newser.com
Ranking MacroGenics Inc. among high performing stocks via tools2025 Key Highlights & Entry Point Confirmation Alerts - newser.com
What MACD and RSI say about MacroGenics Inc.Weekly Volume Report & High Yield Equity Trading Tips - newser.com
Applying sector rotation models to MacroGenics Inc.July 2025 PreEarnings & AI Enhanced Trading Alerts - newser.com
How MacroGenics Inc. stock performs in high volatility marketsQuarterly Performance Summary & Fast Momentum Entry Tips - newser.com
Combining machine learning predictions for MacroGenics Inc.Short Setup & AI Powered Market Trend Analysis - newser.com
Chart overlay techniques for tracking MacroGenics Inc.2025 Risk Factors & AI Based Trade Execution Alerts - newser.com
Will MacroGenics Inc. stock recover after recent dropJuly 2025 Trade Ideas & Proven Capital Preservation Methods - newser.com
How to use Fibonacci retracement on MacroGenics Inc.July 2025 Closing Moves & Proven Capital Preservation Tips - newser.com
Will MacroGenics Inc. stock maintain growth storyEarnings Growth Report & Community Verified Swing Trade Signals - newser.com
MacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Can MacroGenics Inc. stock sustain market leadership2025 Trade Ideas & Fast Entry Momentum Trade Alerts - newser.com
Detecting support and resistance levels for MacroGenics Inc.2025 Volatility Report & Safe Capital Preservation Plans - newser.com
Will MacroGenics Inc. stock benefit from automationWeekly Investment Recap & Entry Point Confirmation Signals - newser.com
MacroGenics’ MGD024 Study: A New Hope for Blood Cancer Treatment? - TipRanks
MacroGenics’ Lorigerlimab Study: A Potential Game-Changer in Cancer Treatment? - TipRanks
Technical analysis overview for MacroGenics Inc. stockPortfolio Return Summary & AI Driven Stock Reports - newser.com
MacroGenics (MGNX) Expected to Announce Earnings on Tuesday - MarketBeat
MacroGenics (NASDAQ:MGNX) Stock Price Crosses Above Fifty Day Moving AverageHere's Why - MarketBeat
Will MacroGenics Inc. stock outperform tech sector in 2025Quarterly Profit Report & Real-Time Volume Spike Alerts - fcp.pa.gov.br
Macrogenics Inc Stock (MGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):